Juho Joutsa1, Juha O Rinne2, Bruce Hermann3, Mira Karrasch4, Anu Anttinen5, Shlomo Shinnar6, Matti Sillanpää7. 1. Turku PET Centre, Turku University Hospital, Turku, Finland 2Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland3Department of Clinical Neurophysiology, Turku University Hospital, Turku, Finland4now with the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown. 2. Turku PET Centre, Turku University Hospital, Turku, Finland 2Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland. 3. Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison. 4. Department of Psychology, Åbo Akademi University, Turku, Finland. 5. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland. 6. Department of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York8Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York9Department of Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. 7. Department of Public Health, University of Turku, Turku, Finland11Department of Child Neurology, University of Turku, Turku, Finland.
Abstract
Importance: The effect of childhood epilepsy on later-life cognitive and brain health is an unclear and little-explored issue. Objective: To determine whether adults with a history of childhood-onset epilepsy exhibit increased brain amyloid accumulation, possibly predisposing to accelerated cognitive impairment or even frank cognitive disorders in later life. Design, Setting, and Participants: Forty-one adults from a population-based cohort of individuals with childhood-onset epilepsy in southwestern Finland, together with 46 matched population-based controls, underwent amyloid ligand carbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography after long-term prospective follow-up. The PiB uptake was quantified as a region to cerebellar cortex ratio. Tracer uptake was evaluated visually and analyzed voxel by voxel over the entire brain to investigate the spatial distribution of amyloid deposition. The study was conducted from May 2011 to October 2013; data analysis was performed from January 2014 to October 2016. Main Outcomes and Measures: Brain amyloid accumulation. Results: The 41 individuals with epilepsy were originally enrolled in the Turku Adult Childhood Onset Epilepsy study at the mean (SD) age of 5.1 (4.5) years (range, 0-14 years). After a mean 52.5 (4.0) years of follow-up, the participants were evaluated (26 [63%] were women; the mean [SD] age was 56.0 [4.3] years). Nine individuals with childhood-onset epilepsy (22%) and 3 control participants (7%) had a visually abnormal PiB scan showing high cortical uptake in at least 1 of the evaluated brain regions (P = .04). In semiquantitative analyses, there was a significant interaction effect indicating higher prefrontal cortex uptake in apolipoprotein E (APOE) ε4 allele carriers than in noncarriers in participants (mean [SD], 1.66 [0.41] vs 1.43 [0.15]) compared with controls (1.40 [0.26) vs 1.41 [0.12]) (group × APOE interaction, F = 6.8; P = .01). In addition, there was a significant group effect showing higher tracer uptake in participants compared with controls (group effect, F = 8.0; P = .006). Conclusions and Relevance: Adults with childhood-onset epilepsy, particularly APOE ε4 carriers, have an increased brain amyloid load at late middle age. Thus, epilepsy is linked with a biomarker that might be related to accelerated brain aging and can be considered a neurobiological predisposition to later-life cognitive disorders.
Importance: The effect of childhood epilepsy on later-life cognitive and brain health is an unclear and little-explored issue. Objective: To determine whether adults with a history of childhood-onset epilepsy exhibit increased brain amyloid accumulation, possibly predisposing to accelerated cognitive impairment or even frank cognitive disorders in later life. Design, Setting, and Participants: Forty-one adults from a population-based cohort of individuals with childhood-onset epilepsy in southwestern Finland, together with 46 matched population-based controls, underwent amyloid ligand carbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography after long-term prospective follow-up. The PiB uptake was quantified as a region to cerebellar cortex ratio. Tracer uptake was evaluated visually and analyzed voxel by voxel over the entire brain to investigate the spatial distribution of amyloid deposition. The study was conducted from May 2011 to October 2013; data analysis was performed from January 2014 to October 2016. Main Outcomes and Measures: Brain amyloid accumulation. Results: The 41 individuals with epilepsy were originally enrolled in the Turku Adult Childhood Onset Epilepsy study at the mean (SD) age of 5.1 (4.5) years (range, 0-14 years). After a mean 52.5 (4.0) years of follow-up, the participants were evaluated (26 [63%] were women; the mean [SD] age was 56.0 [4.3] years). Nine individuals with childhood-onset epilepsy (22%) and 3 control participants (7%) had a visually abnormal PiB scan showing high cortical uptake in at least 1 of the evaluated brain regions (P = .04). In semiquantitative analyses, there was a significant interaction effect indicating higher prefrontal cortex uptake in apolipoprotein E (APOE) ε4 allele carriers than in noncarriers in participants (mean [SD], 1.66 [0.41] vs 1.43 [0.15]) compared with controls (1.40 [0.26) vs 1.41 [0.12]) (group × APOE interaction, F = 6.8; P = .01). In addition, there was a significant group effect showing higher tracer uptake in participants compared with controls (group effect, F = 8.0; P = .006). Conclusions and Relevance: Adults with childhood-onset epilepsy, particularly APOE ε4 carriers, have an increased brain amyloid load at late middle age. Thus, epilepsy is linked with a biomarker that might be related to accelerated brain aging and can be considered a neurobiological predisposition to later-life cognitive disorders.
Authors: Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price Journal: J Nucl Med Date: 2005-12 Impact factor: 10.057
Authors: Bruce Hermann; Michael Seidenberg; Mark Sager; Cynthia Carlsson; Barry Gidal; Raj Sheth; Paul Rutecki; Sanjay Asthana Journal: Epilepsia Date: 2007-11-21 Impact factor: 5.864
Authors: Bruce P Hermann; Michael Seidenberg; Christian Dow; Jana Jones; Paul Rutecki; Abhik Bhattacharya; Brian Bell Journal: Ann Neurol Date: 2006-07 Impact factor: 10.422
Authors: Mira Karrasch; Petri Tiitta; Bruce Hermann; Juho Joutsa; Shlomo Shinnar; Juha Rinne; Anu Anttinen; Matti Sillanpää Journal: J Int Neuropsychol Soc Date: 2017-01-10 Impact factor: 2.892
Authors: John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun Journal: Arch Neurol Date: 2009-12
Authors: Ville Leinonen; Irina Alafuzoff; Sargo Aalto; Timo Suotunen; Sakari Savolainen; Kjell Någren; Tero Tapiola; Tuula Pirttilä; Jaakko Rinne; Juha E Jääskeläinen; Hilkka Soininen; Juha O Rinne Journal: Arch Neurol Date: 2008-08-11
Authors: Sarah Gourmaud; Haochang Shou; David J Irwin; Kimberly Sansalone; Leah M Jacobs; Timothy H Lucas; Eric D Marsh; Kathryn A Davis; Frances E Jensen; Delia M Talos Journal: Brain Date: 2020-01-01 Impact factor: 13.501
Authors: Matti Sillanpää; Bruce Hermann; Juha O Rinne; Riitta Parkkola; Maiju M Saarinen; Mira Karrasch; Jani Saunavaara; Eero Rissanen; Juho Joutsa; Shlomo Shinnar Journal: Acta Neurol Scand Date: 2021-11-26 Impact factor: 3.915